Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,895.85 +18.80 (+0.24%) Bitcoin USD
64,193.80 +902.69 (+1.43%) CMC Crypto 200
1,379.96 +67.34 (+5.13%)
Treace Medical Concepts, Inc. (TMCI)
| Previous close | 11.27 |
| Open | 11.22 |
| Bid | 10.68 x 100 |
| Ask | 10.76 x 100 |
| Day's range | 10.73 - 11.51 |
| 52-week range | 5.27 - 27.70 |
| Volume | |
| Avg. volume | 413,204 |
| Market cap | 665.193M |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Treace to Present at Bank of America Health Care Conference
Wednesday, May 15, 2024, at 2:20 pm Pacific TimePONTE VEDRA, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fires
- GlobeNewswire
Treace Announces First Annual National Bunion Day
Focus on Foot Health Issue Affecting Millions of People Includes Outreach and Education Efforts to Build Awareness, Reduce Stigma and Correct Misconceptions About This Common Bone DeformityPONTE VEDRA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Pro
- GlobeNewswire
Treace to Report First Quarter 2024 Financial Results
Company to Host Conference Call on Tuesday, May 7, 2024 at 4:30 pm ETPONTE VEDRA, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter of 2024 after the close of trading
